CNS Pharma enters $5.2M ATM offering with A.G.P.; warrants repriced

CNS Pharmaceuticals, Inc.

Entered Sales Agreement with A.G.P. for at-the-market offering of up to $5.2M common stock; commission 3.0%.
Net proceeds to be used for working capital and general corporate purposes.
Waiver from Feb 2024 investor lifts restrictions on ATM; warrant exercise prices reduced.
Effective Aug 1, 2024, exercise price of 587,028 Series A/B warrants lowered to Minimum Price.
Additional 3,263,000 warrants repricing subject to shareholder approval; proxy statement due within 60 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.